---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-055953"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:50:12.886068+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports SENTI-202 Phase 1 data: 50% ORR, 42% CR/CRh at RP2D; receives FDA RMAT designation

## Summary
- In 18 evaluable R/R AML patients, SENTI-202 achieved 50% ORR and 42% CR/CRh at RP2D; 100% of CRs MRD negative and median duration of CR 7.6 months.
- SENTI-202 was well-tolerated with no DLTs, no drug-related SAEs, and most AEs hematologic consistent with lymphodepletion.
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202, adding to prior Orphan Drug Designation.
- Logic Gate mechanism validated: selective killing of AML blasts/LSCs while sparing healthy hematopoietic stem/progenitor cells.
- Company to host investor call Dec 9 at 8 AM ET; SENTI-202 potential for pivotal studies and expansion into newly diagnosed AML, pediatric AML, MDS.

## SEC filing metadata
- accession: 0001628280-25-055953
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828025055953/0001628280-25-055953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828025055953/snti-20251209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-055953
- JSON: https://secwatch.observer/filing/0001628280-25-055953.json
- Plain text: https://secwatch.observer/filing/0001628280-25-055953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.